Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010 (2010), Article ID 915046, 7 pages
http://dx.doi.org/10.1155/2010/915046
Research Article

Association of ABCC2 and CDDP-Resistance in Two Sublines Resistant to CDDP Derived from a Human Nasopharyngeal Carcinoma Cell Line

1Cancer Research Institute, Southern Medical University, Guangzhou City, Guangdong Province 510515, China
2Postdoctoral Station of Clinical Medicine, Medical College, Jinan University, Guangzhou City, Guangdong Province 510632, China
3Pathology Department, Medical College, Jinan University, Guangzhou City, Guangdong Province 510632, China

Received 16 December 2009; Accepted 8 April 2010

Academic Editor: William J. Hoskins

Copyright © 2010 Si Ming Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Wu, X. Xiao, P. Zhao et al., “Minicircle-IFN? induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma,” Clinical Cancer Research, vol. 12, no. 15, pp. 4702–4713, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Her, “Nasopharyngeal cancer and the southeast Asian patient,” American Family Physician, vol. 63, no. 9, pp. 1776–1785, 2001. View at Google Scholar · View at Scopus
  3. A. Ahmad and S. Stefani, “Distant metastases of nasopharyngeal carcinoma: a study of 256 male patients,” Journal of Surgical Oncology, vol. 33, no. 3, pp. 194–197, 1986. View at Google Scholar · View at Scopus
  4. A. W. M. Lee, W. H. Lau, S. Y. Tung et al., “Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 6966–6975, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. K. C. Ngan, H. H. Y. Yiu, W. H. Lau et al., “Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study,” Annals of Oncology, vol. 13, no. 8, pp. 1252–1258, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. I. W. Dimery and W. K. Hong, “Overview of combined modality therapies for head and neck cancer,” Journal of the National Cancer Institute, vol. 85, no. 2, pp. 95–111, 1993. View at Google Scholar · View at Scopus
  7. G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, and M. M. Gottesman, “Targeting multidrug resistance in cancer,” Nature Reviews Drug Discovery, vol. 5, no. 3, pp. 219–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Dean, A. Rzhetsky, and R. Allikmets, “The human ATP-binding cassette (ABC) transporter superfamily,” Genome Research, vol. 11, no. 7, pp. 1156–1166, 2001. View at Google Scholar · View at Scopus
  9. K. Taniguchi, M. Wada, K. Kohno et al., “A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation,” Cancer Research, vol. 56, no. 18, pp. 4124–4129, 1996. View at Google Scholar · View at Scopus
  10. S. M. Xie, W. Y. Fang, Z. Liu et al., “Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin,” Journal of Translational Medicine, vol. 6, article 55, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Thomas and H. M. Coley, “Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein,” Cancer Control, vol. 10, no. 2, pp. 159–165, 2003. View at Google Scholar · View at Scopus
  12. N.-N. Zhou, X.-F. Zhu, J.-M. Zhou et al., “2-methoxyestradiol induces cell cycle arrest and apoptosis of nasopharyngeal carcinoma cells,” Acta Pharmacologica Sinica, vol. 25, no. 11, pp. 1515–1520, 2004. View at Google Scholar · View at Scopus
  13. X. Wu, W. Fan, S. Xu, and Y. Zhou, “Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells,” Clinical Cancer Research, vol. 9, no. 16, pp. 5874–5879, 2003. View at Google Scholar · View at Scopus
  14. Y. Ishida, T. Ohtsu, H. Hamada et al., “Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16,” Japanese Journal of Cancer Research, vol. 80, no. 10, pp. 1006–1013, 1989. View at Google Scholar · View at Scopus
  15. X. Zheng, G. Shen, X. Yang, and W. Liu, “Most C6 cells are cancer stem cells: evidence from clonal and population analyses,” Cancer Research, vol. 67, no. 8, pp. 3691–3697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. A. Seyhan, A. V. Vlassov, H. Ilves et al., “Complete, gene-specific siRNA libraries: production and expression in mammalian cells,” RNA, vol. 11, no. 5, pp. 837–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Smith, K. Rangaraj, R. Simpson et al., “Quantitative analysis of the expression of ACAT genes in human tissues by real-time PCR,” Journal of Lipid Research, vol. 45, no. 4, pp. 686–696, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. D. N. Krag, R. Kusminsky, E. Manna et al., “The detection of isolated tumor cells in bone marrow comparing bright-field immunocytochemistry and multicolor immunofluorescence,” Annals of Surgical Oncology, vol. 12, no. 9, pp. 753–760, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Gao, C. Lu, C. Xu, Y. Tao, B. Cong, and X. Ni, “Differential regulation of prostaglandin production mediated by corticotropin-releasing hormone receptor type 1 and type 2 in cultured human placental trophoblasts,” Endocrinology, vol. 149, no. 6, pp. 2866–2876, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. S. N. Lanjwani, R. Zhu, M. Y. Khuhawar, and Z. Ding, “High performance liquid chromatographic determination of platinum in blood and urine samples of cancer patients after administration of cisplatin drug using solvent extraction and N,N-bis(salicylidene)-1,2-propanediamine as complexation reagent,” Journal of Pharmaceutical and Biomedical Analysis, vol. 40, no. 4, pp. 833–839, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Surowiak, V. Materna, I. Kaplenko et al., “Nuclear membraneous localization of ABCC2(MRP2,cMOAT) in ovarian carcinoma cells can correlate with resistance to platinum-containing drugs and clinical outcome,” Proceedings of the American Association for Cancer Research, vol. 47, pp. 597–603, 2006. View at Google Scholar
  23. D. Keppler, I. Leier, and G. Jedlitschky, “Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2,” Biological Chemistry, vol. 378, no. 8, pp. 787–791, 1997. View at Google Scholar · View at Scopus
  24. R. Evers, M. Kool, L. van Deemter et al., “Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA,” The Journal of Clinical Investigation, vol. 101, pp. 1310–1319, 1998. View at Google Scholar
  25. P. Borst, M. Kool, and R. Evers, “Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?” Seminars in Cancer Biology, vol. 8, no. 3, pp. 205–213, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Kool, M. de Haas, G. L. Scheffer et al., “Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines,” Cancer Research, vol. 57, no. 16, pp. 3537–3547, 1997. View at Google Scholar · View at Scopus
  27. A. D. Guminski, R. L. Balleine, Y.-E. Chiew et al., “MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma,” Gynecologic Oncology, vol. 100, no. 2, pp. 239–246, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Materna, A. Stege, P. Surowiak, A. Priebsch, and H. Lage, “RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells,” Biochemical and Biophysical Research Communications, vol. 348, no. 1, pp. 153–157, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Lopez-Flores, R. Jurado, and P. Garcia-Lopez, “A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples,” Journal of Pharmacological and Toxicological Methods, vol. 52, no. 3, pp. 366–372, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Liscovitch and Y. Lavie, “Cancer multidrug resistance: a review of recent drug discovery research,” IDrugs, vol. 5, no. 4, pp. 349–355, 2002. View at Google Scholar · View at Scopus
  31. M. Böhme, M. Büchler, M. Müller, and D. Keppler, “Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane,” FEBS Letters, vol. 333, no. 1-2, pp. 193–196, 1993. View at Publisher · View at Google Scholar · View at Scopus